Cyclica/Institute Materia Medica Drug Repurposing Initiative

Repurposing

Research Institution

Institute Materia Medica, Chinese Academy of Medical Sciences

Description

Chinese medical research institution in Beijing, Institute of Materia Medica, Chinese Academy of Medical Sciences, enters a strategic collaboration with Canadian-based biotechnology company Cyclica to discover antiviral drug candidates for COVID-19 and explore opportunities to design multi-targeted antiviral compounds. While current efforts to develop new medicines through generative approaches for the COVID-19 outbreak can result in possible therapies, new drug development efforts can be resource intensive and require a number of years of both pre-clinical and clinical testing. As such, drug repurposing offers a more effective strategy that suits the urgency of the need for treatments of COVID-19. Artificial intelligence (AI) approaches to drug repurposing can be deployed to further expedite the recommendation of potential therapeutic solutions.

Cyclica used its proprietary deep learning engine, MatchMakerTM, to screen a collection of more than 6,700 FDA-approved drugs and drug candidates with at least Phase I clinical data against the structurally-characterized human proteome. MatchMaker is trained on millions of known human drug-target interactions (DTI) in addition to structural data. The resulting first-in-class database, named PolypharmDB, is a library of clinically assessed molecules and their polypharmacological profiles that can be used to identify repurposing opportunities for drug candidates.

Leveraging PolypharmDB and MatchMaker, Cyclica's scientists investigated both human targets as well as viral proteins with potential therapeutic relevance for COVID-19 in rapid fashion. The result is a set of molecules that are predicted to interact with the putative therapeutic targets for COVID-19. While the results are promising, modelling viral proteins pushes MatchMaker beyond established benchmarks, increasing the uncertainty around predictions for those targets. The prioritized set of molecules resulting from the interrogation of PolypharmDB represents an actionable collection of molecules primed for testing.

In this collaboration, China’s Institute of Materia Medica will conduct in vitro and in vivo antiviral assessment for molecules proposed by Cyclica. In addition, the two parties will cooperate in a longer-term effort to design multi-target antiviral compounds with the goal of reducing drug resistance.

Research Team

Unknown

Project Details

Funding Sources

Government, Private

Project Phases

Planned Time to Trials

Additional Resources

Needs

Hover for more information.
No items found.

Get In Touch

Directly connect with the responsible researchers by sending a message.
Thank you! Your message has been received and will be forwarded to the research team!
Oops! Something went wrong while submitting the form.